Tag: Severe sickle cell disease

Browse exclusive Tags!

FDA Grants RMAT Designation to Editas Medicine’s EDIT-301 for Severe Sickle Cell Disease, US

The FDA grants RMAT designation to Editas Medicine's EDIT-301 for severe sickle cell disease. Learn about the potential life-changing benefits of this innovative gene editing medicine.

Popular

Subscribe

spot_imgspot_img